Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 01 May 2020

by | May 4, 2020

Significant biosimilar activities this week include

23 April 2020 | Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02.

28 April 2020 | Mylan and Biocon launched Fulphila® (pegfilgrastim) in Canada. Fulphila® is approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

29 April 2020 | Gedeon Richter announced it has entered an asset purchase agreement with Mycenax Biotech for the purchase of a biosimilar tocilizumab product. Under the agreement, Richter will receive worldwide rights to develop, manufacture and commercialise the product which is expected to reach global markets in 2025.

30 April 2020 | Amgen filed suit against Hospira and Pfizer in the District Court of Delaware, alleging infringement of US patent 10,577,392, relating to the manufacture of Neupogen® (filgrastim). Interestingly, the patent was only granted on March 03, 2020, nearly 2 years after Hospira launched Nivestym®.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News